A Process for the Emulation of Comparative Oncology Trials with Real-world Evidence (ENCORE)

**Authors**: Janick Weberpals1, Kenneth L. Kehl2, Donna R. Rivera3, …, Sebastian Schneeweiss1, Shirley V. Wang1

Author affiliations:

1 Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

2 Dana-Farber, …, USA

3 Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA

**Correspondence:**

Shirley V. Wang, PhD

Division of Pharmacoepidemiology and Pharmacoeconomics,

Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School,

1620 Tremont Street, Suite 3030-R, Boston, MA 02120, USA

Phone: +1 617-278-0932

Fax: + 1 617-232-8602

Email: <SWANG1@BWH.HARVARD.EDU>

**Article type:** Review

**Word count:** xxx words / xxx words

**Tables:** x

**Figures:** x

**Supplementary material:** Supplementary tables and figures

**Short running title**: …

**Keywords:** Oncology, Real-World Evidence, Trial emulation, EHR

**Funding Statement:** This project was supported by …

**Competing Interests Statement:** Dr. Weberpals is now an employee of AstraZeneca and owns stocks in AstraZeneca. Dr. Wang has consulted ad hoc for Exponent Inc. and MITRE a federally funded research center for the Centers for Medicare and Medicaid Services on unrelated work. Dr. Schneeweiss is participating in investigator-initiated grants to the Brigham and Women’s Hospital from Boehringer Ingelheim, Takeda, and UCB unrelated to the topic of this study. He owns equity in Aetion Inc., a software manufacturer. He is an advisor to Temedica GmbH, a patient-oriented data generation company. His interests were declared, reviewed, and approved by the Brigham and Women’s Hospital in accordance with their institutional compliance policies.

**Data sharing statement:** …

**Analytic code sharing statement:** …

***Proposed target journals:*** *JCO CCI => JAMA Network Open => CPT*

*Manuscript last updated: 2024-12-08 19:46:09.072875*

# Abstract

xxx words/xxx words

…

# Background

Randomized controlled trials (RCTs) have been the gold standard for establishing the efficacy and safety of medical products. With the advent of the the 21st Century Cures Act directive1, the Food and Drug Administration (FDA) established a framework to increasingly consider real-world evidence (RWE) generated from routine-care health data such as electronic health records (EHR) to evaluate and contextualize the comparative safety and effectiveness of novel cancer therapies.2 With 21% of all approvals, oncology was the disease area with the most FDA drug approvals in 2023,3 and especially in the field of precision oncology, RWE has a large potential to complement evidence coming from RCTs. Potential use cases comprise the assessment of effectiveness in patient populations that are underrepresented in RCTs, the construction of external control arms in single-arm trials where active recruitment may not be feasible or the discovery of biomarkers among pan-tumor populations that harbor specific genomic and immuno-pathological signatures.

However, the validity and transportability of results derived betwen RWE studies and RCTs can depend on many factors and frequently referenced limitations include missing data, small sample sizes, data discontinuity4, 5, rapid changes in guideline treatment patterns and the inability to measure and emulate common eligibility criteria and prognostic factors in real-world data (RWD).6 While there are already published examples of oncology trial emulations6–8, a systematic and scaled approach to emulate a diverse set of different oncology trials in various heterogeneous databases is necessary to gain confidence in the accuracy of RWE studies and to provide an answer as to which questions can be validly answered.

The RCT DUPLICATE initiative9 increased our understanding of when RWE studies can come to causal conclusions on treatment effects by comparing results against RCTs under the assumption that each RCT finding reflects a causal treatment effect. In settings where the RCT designs could be emulated well, RWE studies came to the same conclusions.10 However, prior work from RCT-DUPLICATE has focused primarily on emulating trials in the cardio-metabolic, renal, and pulmonary clinical areas using claims databases.

The *Emulation of Comparative Oncology Trials with Real-world Evidence* (**ENCORE**) project11 aims to extend this work to the field of oncology which comes with its own unique set of challenges which must be systematically explored and understood. Building on a process co-developed with the FDA through RCT DUPLICATE9, this expansion to oncology is going to emulate 12 randomized clinical trials using multiple EHR data sources. The process includes an emphasis on transparency with documented assessment of data fitness of the RWD source for each trial12, 13 and the conduct of extensive sensitivity analyses to assess robustness of findings and trial eligibility criteria.

The objectives of this project are to develop state-of-the-art methodological approaches and apply these to create insights that may provide guidance on the potential use of RWE for regulatory science in oncology. This includes the systematic evaluation of the suitability of data in relation to the study design and statistical analysis by emulating 12 oncology trials across four cancers and assessing the agreement of treatment effect estimates between RCTs and their respective emulations.

In this process paper, we describe the design and process for the selection of the 12 oncology RCTs, the assessment of the database quality and selection, protocol development, study design and statistical analysis and final agreement metrics to evaluate the concordance between RCTs and emulations.

# Methods

A visual summary of the entire systematic process from trial selection to final results is provided in [Figure 1](#fig-process).

## Trial selection

The focus of ENCORE is to maximize potential learnings on when RWE studies can or cannot yield similar results compared to RCTs. To that end, the emphasis of the project is on trials of therapies for the most common cancers and/or cancers for which there has been substantial therapeutic development in recent years. After careful review and exchange with clinical and regulatory experts, four cancer indications were identified including lung cancer, breast cancer, colorectal cancer and multiple myeloma. For each cancer we aim to conduct three trial emulations which will be implemented using multiple databases accessible for the scope of this project (i.e. the total number of emulations will equal 12 trials x *n* databases which are found fit-for-purpose for each trial).

The trial selection will follow a semi-automated process for which we will document the eligibility criteria resulting in a CONSORT diagram showing reasons for excluding RCTs. The search will be conducted using the AACT database which is s a publicly available relational database developed and maintained by the Clinical Trials Transformation Initiative (CTTI) which contains all information (protocol and result data elements) about every study registered on ClinicalTrials.gov.14 To identify eligible trials, we will use a combined search query strategy of the National Library of Medicine (NLM)-controlled *MeSH* term and a free keyword search for the respective cancer indication in the *conditions*, *studies* and *detailed\_descriptions* fields of each trial entry on ClinicalTrials.gov.

Eligible trials need to fulfill the following basic criteria:

* Interventional
* Randomized
* Intervention model: parallel assignment
* Industry-sponsored
* Trial start in 2011 or later
* Primary purpose was to study treatment effects
* Overall survival must be one of the endpoints reported (either as hazard ratio or median overall survival time)
* Recruitment status: ‘Completed’ or ‘Active, not recruiting’
* Feasibility and clinical relevance

The rationale and operationalization of each criterion is listed in detail in [Table 1](#tbl-criteria). We will mainly consider pivotal interventional, randomized trials after 2011 since treatment guidelines among studied cancer indications have undergone significant changes in recent years. Due to the rapid adoption of new breakthrough therapies in routine care, it is unlikely to find patients who may be still treated with outdated treatment regimens in the real-world. In parallel, trial results should have also not been published too recently in order to allow for enough data and follow-up time accrual in databases used for this project. A further focus is on trials that have reported overall survival (OS) as one of the pre-specified endpoints in the protocol. Although there have been substantial methodological advancements to increase our understanding on the emulation and comparison of real-world progression-free survival (PFS) and objective response rates (ORR) to a RECISTv1.115-based PFS and ORR assessment in RCTs16, 17, imaging-based evaluations still hold a level of granularity which may not be necessarily reflected in chart-abstracted assessments of a patient’s progression in routine care.18, 19 Given the large number of other methodological challenges like missing data, small sample sizes, data discontinuity and rapidly changing guideline treatments, the scope of this project was to focus on the emulation of OS as the endpoint of interest.

While most trial-eligibility criteria can be operationalized in an automated fashion, the last criterion on emulation feasibility and clinical relevance involves extensive human review. The critical points considered in this step include a thorough feasibility assessment of the data fitness19, sample size considerations and the assessment if critical eligibility criteria (e.g., biomarker status) and prognostic factors (e.g., ECOG performance score) are measurable and can be balanced using propensity score matching or weighting methods.20 Lastly, trial candidates are ranked and shortlisted into primary and runner-up candidates based on their clinical and regulatory relevance.

A list of tentative, shortlisted primary candidates is presented in [Table 2](#tbl-rcts) and the corresponding selection process is illustrated in the CONSORT diagrams (Supplementary Figures 1-4). Naturally, the majority trials will cover advanced or metastatic cancer populations since a large proportion of drug development efforts have focused on these settings in recent years. A key learning that we aim to foster with the shortlisted trials is to achieve a better understanding how different disease settings (early, late), line settings ([neo]adjuvant, first line, advanced lines of therapy), therapy protocols (monotherapy, combination therapy) and population characteristics (simple versus complex genetic or immunological signatures) can be emulated using RWD. If ongoing feasibility assessments indicate that these trials cannot be emulated with high enough confidence, runner-up candidates will be considered instead.

## Databases

The ENCORE project will utilize data from a total four different oncology-specific electronic health records (EHR)-derived specialty oncology data sources: ConcertAI, COTA, Flatiron Health, McKesson/Ontada. All available databases draw from a comprehensive national sample of patients with cancer in the US with detailed EHR-derived information on the information necessary to study medication effectiveness in oncology. For ENCORE, not all databases will be available for each cancer indication and the names of the databases will be blinded and referred to as ENCORE DataBase (EDB) 1, 2, 3 and 4 for the final reporting of results. If more than one database is considered fit-for-purpose for a respective trial emulation, the best possible analytic model will be employed for each database separately and final treatment effect estimates will be pooled using a meta-analytic approach.

## Protocol development

For each shortlisted and selected RCT, a detailed protocol, pre-specifying key elements of the trial emulation, will be developed following the HARPER protocol template21 and will be registered on ClinicalTrials.gov after careful review by a clinical and FDA regulatory expert panel. Following the target trial emulation framework, we will provide an explicit statement and rationale on how each element will be emulated including database selection, covariate measurement, operationalization of key eligibility criteria, study design, data analysis and causal contrasts of interest.22, 23 Since it is common that oncology RCTs update OS estimates periodically based on accrued follow-up time, the protocol will give a brief summary of each emulated RCT and specify which target OS estimates will be used to compare agreement metrics to (see [Section 2.6](#sec-agreement-metrics)). All eligibility criteria will be extracted based on publicly available protocols and statistical analysis plans of the selected RCT.

### Emulation feasibility

**Fit-for-purpose data.** Real-world data fitness and emulation feasibility for a given shortlisted candidate trial will be assessed in multiple steps based on guidance of the oncology quality, characterization, and assessment of real-world data (Oncology QCARD) Initiative.19 The first step assesses if relevant variables like exposure/line of therapy, outcomes, and covariates are generally available, measured and operationalizable in routine-care. Since a vast majority of oncological RCTs in recent years have focused on selected, biomarker-defined populations, subtleties in measurement and operationalizability of specific biomarkers must be reflected to ensure a representative and large enough study population. For example, immunotherapies have significantly changed the cancer treatment landscape since the approval of the first PD-L1 inhibitor in 2015. With many trials that have followed thereafter, the operationalization of the expression of the PD-L1 biomarker in RCTs (e.g., as a percent staining, tumor proportion score or combined positive score) has also evolved since then and PD-L1 ’*positivity’* may have different definitions across calendar years based on different cut-off values.

According to the *Structured Process to Identify Fit-For-Purpose Data* (SPIFD) framework13, the next step will outline tables that describe how eligibility criteria will be ascertained using a color-coded heatmap that will indicate the level of confidence on how well each criterion can be emulated in each selected database. As there are general eligibility criteria in oncology trials which either won’t be possible to emulate (e.g., physician-assessed survival prognosis of xy months) or that are clinically not relevant for the emulation of the trial (e.g., male patients should be willing to use barrier contraception), the study team will decide on key eligibility criteria for the emulation of the trial.

We will additionally provide a definition on how exposures, outcomes and covariates are exactly defined and operationalized in each respective database. There will be special emphasis on how exposure, in context of their respective disease and line of therapy settings, and the OS outcome will be emulated. For all considered databases, the OS endpoint is typically a composite that is derived from different sources comprising EHR abstractions, social security death index, obituary and other linkages. Given that not all relevant sources that provide mortality data are synchronized and updated uniformly, sensitivity analyses with more conservative (i.e., earlier) censoring dates will be considered for each trial emulation to mitigate the potential impact of ghost-time bias.24

**Descriptives and data exploration.** Critical aspects when emulating oncology trials are the choice and estimation of the appropriate estimand of interest.25 Particularly when emulating pivotal trials of paradigm-changing treatments, multiple aspects need to be considered such as the contemporaneity of the (historical) control cohort, the adoption rate of the novel intervention in routine care, the magnitude of the clinical treatment benefit and the rate in which (particularly patients in the control arm) discontinue or cross-over to the interventional treatment, which could lastly bias emulated treatment effects towards the null. To that end, comprehensive data explorations will be performed as part of the protocol development to contextualize these parameters and (if reported) draw comparisons to the emulated trial. Example for such standard diagnostics are visualized in [Figure 2](#fig-initiators).

The distribution of patient characteristics, stratified by exposure status, will be examined in Table 1’s before and after applying eligibility criteria and contrasted with the distributions of patient characteristics of the original RCT. Initial propensity score matching or weighting methods will be applied to ensure that measured pre-exposure covariates can be balanced, eposure cohorts are conditiionally exchangeable at baseline and resulting sample sizes are still sufficient after matching or weighting. At this stage, all exploratory analyses will be conducted blinded towards the outcome to not bias any study design and analytic choices based on known outcome information.

**Statistical power**. Causal analyses of observational data may not have the same pre-requisites in terms of formal hypothesis testing and statistical power than RCTs since the number of ‘recruited’ patients is given and cannot be influenced.26 For this project, however, statistical power is a critical to assess the feasibility that a comparison of agreement metrics of estimated parameters between RCT and RWD with sufficient precision can be made. Since the main outcome of interest is defined as time to all-cause mortality (OS), the estimation of the statistical power is driven by the number of events rather than the number of patients. To assess if the unstratified number of events is sufficient such that a significant difference can be detected based on the original RCT-reported hazard ratio (HR), the statistical power will be estimated using Schoenfeld’s sample-size formula for the proportional-hazards regression model.27, 28

## Study design and statistical analysis

The main parameters of interest in ENCORE are the marginal hazard ratio (HR) coefficient for the treatment comparison for time to all-cause mortality (OS)29 and the corresponding Kaplan-Meier median survival time estimates.30 The median survival time is defined as the first time at which the the survival probability drops below 50%.31

32

## Agreement metrics

# Discussion

…

## Conclusions

…

# References

**1**. Framework for FDA’s real-world evidence program (last accessed 11/28/2024) [Internet], 2018Available from: <https://www.fda.gov/media/120060/download?attachment>

**2**. Purpura CA, Garry EM, Honig N, et al: The role of real-world evidence in FDA-approved new drug and biologics license applications. Clinical Pharmacology & Therapeutics 111:135–144, 2022

**3**. Senior M: Fresh from the biotech pipeline: Record-breaking FDA approvals. Nature Biotechnology, 2024

**4**. Merola D, Schneeweiss S, Schrag D, et al: An algorithm to predict data completeness in oncology electronic medical records for comparative effectiveness research [Internet]. Annals of Epidemiology 76:143–149, 2022Available from: <http://dx.doi.org/10.1016/j.annepidem.2022.07.007>

**5**. Joshua Lin K, Jin Y, Gagne J, et al: Longitudinal data discontinuity in electronic health records and consequences for medication effectiveness studies. Clinical Pharmacology & Therapeutics 111:243–251, 2022

**6**. Rider JR, Wasserman A, Slipski L, et al: Emulations of oncology trials using real-world data: A systematic literature review. American journal of epidemiology kwae346, 2024

**7**. Merola D, Campbell U, Gautam N, et al: The aetion coalition to advance real-world evidence through randomized controlled trial emulation initiative: oncology. Clinical Pharmacology & Therapeutics 113:1217–1222, 2023

**8**. Merola D, Campbell U, Lenis D, et al: Calibrating observational health record data against a randomized trial. JAMA Network Open 7:e2436535–e2436535, 2024

**9**. Wang SV, Schneeweiss S, Franklin JM, et al: [Emulation of randomized clinical trials with nonrandomized database analyses: Results of 32 clinical trials](https://doi.org/10.1001/jama.2023.4221). Jama 329:1376–1385, 2023

**10**. Heyard R, Held L, Schneeweiss S, et al: Design differences and variation in results between randomised trials and non-randomised emulations: Meta-analysis of RCT-DUPLICATE data [Internet]. BMJ medicine 3, 2024Available from: <https://doi.org/10.1136/bmjmed-2023-000709>

**11**. Calibrating real-world evidence studies in oncology against randomized trials: ENCORE (last accessed 11/28/2024) [Internet], 2024Available from: <https://www.fda.gov/about-fda/oncology-center-excellence/calibrating-real-world-evidence-studies-oncology-against-randomized-trials-encore>

**12**. Rivera DR, Eckert JC, Rodriguez-Watson C, et al: The oncology QCARD initiative: Fostering efficient evaluation of initial real-world data proposals. Pharmacoepidemiology and Drug Safety 33:e5818, 2024

**13**. Gatto NM, Campbell UB, Rubinstein E, et al: The structured process to identify fit-for-purpose data: A data feasibility assessment framework. Clinical Pharmacology & Therapeutics 111:122–134, 2022

**14**. Tasneem A, Aberle L, Ananth H, et al: The database for aggregate analysis of ClinicalTrials. Gov (AACT) and subsequent regrouping by clinical specialty. PloS one 7:e33677, 2012

**15**. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European journal of cancer 45:228–247, 2009

**16**. Ton TGN, Pal N, Trinh H, et al: Replication of overall survival, progression-free survival, and overall response in chemotherapy arms of nonâsmall cell lung cancer trials using real-world data [Internet]. Clinical Cancer Research 28:2844–2853, 2022Available from: <https://doi.org/10.1158/1078-0432.CCR-22-0471>

**17**. McKelvey BA, Garrett-Mayer E, Rivera DR, et al: Evaluation of real-world tumor response derived from electronic health record data sources: A feasibility analysis in patients with metastatic non–small cell lung cancer treated with chemotherapy. JCO Clinical Cancer Informatics 8:e2400091, 2024

**18**. Chen L, Davis R, Lee J, et al: Comparison of response from RECIST1.1 and abstraction in real-world patients with lung cancer. [Internet]. Journal of Clinical Oncology 41:e21194–e21194, 2023Available from: <https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e21194>

**19**. Rivera DR, Henk HJ, Garrett-Mayer E, et al: The friends of cancer research real-world data collaboration pilot 2.0: Methodological recommendations from oncology case studies. Clinical Pharmacology & Therapeutics 111:283–292, 2022

**20**. Brookhart MA, Schneeweiss S, Rothman KJ, et al: Variable selection for propensity score models. American journal of epidemiology 163:1149–1156, 2006

**21**. Wang SV, Pottegård A, Crown W, et al: HARmonized protocol template to enhance reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force [Internet]. Value in Health 25:1663–1672, 2022Available from: <https://doi.org/10.1016/j.jval.2022.09.001>

**22**. Hernán MA, Wang W, Leaf DE: Target trial emulation: A framework for causal inference from observational data. Jama 328:2446–2447, 2022

**23**. Hernán MA, Sauer BC, Hernández-Dı́az S, et al: [Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses](https://doi.org/10.1016/j.jclinepi.2016.04.014). Journal of clinical epidemiology 79:70–75, 2016

**24**. Meyer A-M, Davies J, Taylor M, et al: Open cohorts and ghost-time bias in real world data, in PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, 2020, pp 426–426

**25**. Rufibach K: Treatment effect quantification for time-to-event endpointsEstimands, analysis strategies, and beyond [Internet]. Pharmaceutical Statistics 18:145–165, 2018Available from: <http://dx.doi.org/10.1002/pst.1917>

**26**. Hernán MA: Causal analyses of existing databases: No power calculations required. Journal of clinical epidemiology 144:203–205, 2022

**27**. Schoenfeld D: The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika 68:316–319, 1981

**28**. Schoenfeld DA: Sample-size formula for the proportional-hazards regression model. Biometrics 499–503, 1983

**29**. Cox DR: Regression models and life-tables. Journal of the royal statistical society. Series B (Methodological) 34:187–220, 1972

**30**. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. Journal of the American statistical association 53:457–481, 1958

**31**. Therneau T et al: A package for survival analysis in s. R package version 2:2014, 2015

**32**. Weberpals J, Raman SR, Shaw PA, et al: A principled approach to characterize and analyze partially observed confounder data from electronic health records [Internet]. Clinical Epidemiology 16:329–343, 2024Available from: [https://www.tandfonline.com/doi/abs/10.2147/CLEP.S436131](                    https://www.tandfonline.com/doi/abs/10.2147/CLEP.S436131       )

# Tables

file:////var/folders/c2/q1wb686n6cz5h3gc7jzxw\_9w0000gn/T//Rtmp9MYxvK/file1607f41726028.html screenshot completed

|  |
| --- |
| Table 1: Criteria to select eligible trials for emulation in ENCORE. |

file:////var/folders/c2/q1wb686n6cz5h3gc7jzxw\_9w0000gn/T//Rtmp9MYxvK/file1607f7db385c2.html screenshot completed

|  |
| --- |
| Table 2: Tentative list of randomized controlled trials (RCTs) considered for emulation. |

# Figures

|  |
| --- |
| Figure 1: Systematic process to understand effectiveness claims of oncology trials using real-world evidence. |

[View figure in higher resolution here](https://github.com/janickweberpals/encore-process-manuscript/blob/main/figures/process.png)

Warning in get\_plot\_component(plot, "guide-box"): Multiple components found;  
returning the first one. To return all, use `return\_all = TRUE`.

Saving 5 x 7 in image

|  |
| --- |
| Figure 2: Descriptive drug utilization analyses. |